Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-19-016795
Filing Date
2019-11-12
Accepted
2019-11-12 06:26:08
Documents
42
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 299335
2 ex31-1.htm EX-31.1 17934
3 ex31-2.htm EX-31.2 17925
4 ex32-1.htm EX-32.1 6797
5 ex32-2.htm EX-32.2 6763
  Complete submission text file 0001493152-19-016795.txt   1807466

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE nxen-20190930.xml EX-101.INS 207179
7 XBRL SCHEMA FILE nxen-20190930.xsd EX-101.SCH 29245
8 XBRL CALCULATION FILE nxen-20190930_cal.xml EX-101.CAL 25361
9 XBRL DEFINITION FILE nxen-20190930_def.xml EX-101.DEF 93867
10 XBRL LABEL FILE nxen-20190930_lab.xml EX-101.LAB 196849
11 XBRL PRESENTATION FILE nxen-20190930_pre.xml EX-101.PRE 143303
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

EIN.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55320 | Film No.: 191205865
SIC: 2834 Pharmaceutical Preparations